Glenview Trust Co Buys 191,081 Shares of Boston Scientific Corporation $BSX

Glenview Trust Co boosted its stake in Boston Scientific Corporation (NYSE:BSX) by 631.7% during the first quarter, HoldingsChannel reports. The firm owned 221,332 shares of the medical equipment provider’s stock after buying an additional 191,081 shares during the period. Glenview Trust Co’s holdings in Boston Scientific were worth $13,889,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. FWL Investment Management LLC bought a new position in shares of Boston Scientific in the 2nd quarter worth $26,000. Swiss RE Ltd. bought a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Garton & Associates Financial Advisors LLC bought a new stake in shares of Boston Scientific during the 4th quarter worth $26,000. Bangor Savings Bank grew its position in Boston Scientific by 94.7% in the fourth quarter. Bangor Savings Bank now owns 292 shares of the medical equipment provider’s stock worth $28,000 after acquiring an additional 142 shares in the last quarter. Finally, Sfam LLC purchased a new position in Boston Scientific in the fourth quarter worth $29,000. 89.07% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BSX. Needham & Company LLC lowered their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada cut their price objective on Boston Scientific from $100.00 to $85.00 and set an “outperform” rating for the company in a report on Monday, July 13th. Daiwa Securities Group lowered Boston Scientific from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Stifel Nicolaus dropped their target price on Boston Scientific from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Thursday, June 25th. Finally, The Goldman Sachs Group set a $71.00 target price on Boston Scientific in a research note on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $79.84.

Insider Buying and Selling

In related news, Director David C. Habiger acquired 2,250 shares of the company’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at $776,057.76. This trade represents a 19.35% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Cheryl Pegus bought 1,770 shares of the business’s stock in a transaction dated Wednesday, May 20th. The stock was purchased at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director directly owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ? increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 9,800 shares of company stock worth $554,012 in the last ninety days. 0.34% of the stock is owned by insiders.

Boston Scientific Stock Performance

NYSE BSX opened at $43.86 on Tuesday. The company has a 50-day simple moving average of $47.99 and a two-hundred day simple moving average of $65.29. The company has a quick ratio of 1.22, a current ratio of 1.90 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $42.20 and a 12-month high of $109.50. The firm has a market cap of $65.20 billion, a price-to-earnings ratio of 18.35, a PEG ratio of 0.84 and a beta of 0.58.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.The firm had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. During the same quarter in the previous year, the business earned $0.75 earnings per share. The company’s quarterly revenue was up 11.6% on a year-over-year basis. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts forecast that Boston Scientific Corporation will post 3.35 EPS for the current year.

Boston Scientific announced that its Board of Directors has initiated a share repurchase program on Monday, May 18th that permits the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.